Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5.:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Sharjah :
Bentham Science Publishers,
2016.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Beschreibung: | 1 online resource (328 pages) |
| ISBN: | 9781681082318 1681082314 |
Internformat
MARC
| LEADER | 00000cam a2200000 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn957126295 | ||
| 003 | OCoLC | ||
| 005 | 20240705115654.0 | ||
| 006 | m o d | ||
| 007 | cr |n|---||||| | ||
| 008 | 160820s2016 xx o 000 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d YDX |d EBLCP |d OCLCQ |d OCLCF |d N$T |d AGLDB |d D6H |d OCLCQ |d VTS |d STF |d OCLCQ |d UKSSU |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 019 | |a 956747086 |a 959534990 |a 959649506 |a 1010973709 |a 1087408883 |a 1162192367 |a 1264948669 | ||
| 020 | |a 9781681082318 |q (electronic bk.) | ||
| 020 | |a 1681082314 |q (electronic bk.) | ||
| 035 | |a (OCoLC)957126295 |z (OCoLC)956747086 |z (OCoLC)959534990 |z (OCoLC)959649506 |z (OCoLC)1010973709 |z (OCoLC)1087408883 |z (OCoLC)1162192367 |z (OCoLC)1264948669 | ||
| 050 | 4 | |a RC523 |b .F76 2016 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 7 | |a 616.8/31 |2 23 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Atta-ur-Rahman. | |
| 245 | 1 | 0 | |a Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5. |
| 260 | |a Sharjah : |b Bentham Science Publishers, |c 2016. | ||
| 300 | |a 1 online resource (328 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a PREFACE ; List of Contributors ; Should Physicians Screen for Dementia in the Primary Care Setting? ; INTRODUCTION; SECTION 1: SHOULD WE SCREEN FOR DEMENTIA?; Considerations in Screening for a Disease; Does Dementia Pass Muster as a Disease Worthy of Screening? ; CRITERION 1: How Prevalent and Costly is Alzheimer's disease?; CRITERION 2: Are Early Stages of Dementia not Obvious?; CRITERION 3: Are Screening Tools Cheap and Effective?; CRITERION 4: Does the Potential Harm from a False Positive or False Negative Test Outweigh the Positive Benefit from Screening? | |
| 505 | 8 | |a Criterion 5: Does Earlier Diagnosis of Dementia or Cognitive Impairment Make a Difference?Potential Non-Disease Indirect Benefits of Screening for Dementia; Potential Benefit of Early Detection #1: Alerting Physician to Potential Medication Compliance Problems; Potential Benefit of Early Detection #2: Alerting Physicians to the Risk of Post-Operative Delirium; Potential Benefit of Early Detection #3: Additional Time for Family Planning; Potential Benefit of Early Detection #4: Assessing Patient's Competence at Work and Managing Finances. | |
| 505 | 8 | |a Potential Benefit of Early Detection #5: Identifying Unsafe Drivers Before it is too latePotential Benefit #6-Identification of Potentially Reversible Dementias-and Reversing Them; Potential Benefit #7: Identification of Patients for Research Program Participation; Potential Benefit #8: Establishment of a Cognitive Baseline; The Key Question: Can Earlier Intervention in Dementia Make a Difference?; SECTION 2: BEDSIDE TESTS FOR DEMENTIA SCREENING ; The Mini-Mental State [44]; Montreal Cognitive Assement (MoCA) [47]; The Clock Draw Test; The Mini-Cog [58]. | |
| 505 | 8 | |a Buschke's Memory Impairment Screen [61]Semantic and Lexical Fluency Tasks as Screening Tools; The Hopkins Verbal Learning Test (HVLT) [71]; The Q & E (Quick and Easy); CONCLUSION; NOTES; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Endothelial Dysfunction and Chronic Low-Grade Inflammation as Potential Therapeutic Targets in Dementia Disorders ; INTRODUCTION; Endothelial Dysfunction and Chronic Low-Grade Inflammation as a Possible Link between Cardiometabolic Disorders and Dementia; Endothelial Dysfunction and Dementia. | |
| 505 | 8 | |a Treatment Options Targeting Endothelial Dysfunction and Chronic Low-Grade Inflammation in Dementia DisordersEndothelin Receptor Antagonists; Anti-Inflammatory Drugs; Nonsteroidal Anti-Inflammatory Drugs ; Cytokine Suppressive Anti-Inflammatory Drugs; CONCLUSION; ACKNOWLEDGEMENTS; CONFLICT OF INTEREST; REFERENCES; Recent Clinical Developments in Alzheimer's Disease ; INTRODUCTION; Therapeutic Strategies and Clinical Trials; Cholinergic Hypothesis; Amyloid Cascade Hypothesis; Inflammation in AD ; Metal Dyshomeostasis in AD; Future Development: Challenges and Recent Advances. | |
| 650 | 0 | |a Alzheimer's disease. |0 http://id.loc.gov/authorities/subjects/sh85004080 | |
| 650 | 2 | |a Alzheimer Disease |0 https://id.nlm.nih.gov/mesh/D000544 | |
| 650 | 6 | |a Maladie d'Alzheimer. | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Alzheimer's disease |2 fast | |
| 758 | |i has work: |a Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5 (Text) |1 https://id.oclc.org/worldcat/entity/E39PD39vvcqTypVW8gKYWfbBGd |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Atta-ur-Rahman. |t Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5. |d Sharjah : Bentham Science Publishers, ©2016 |z 9781681082325 |
| 856 | 1 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1511895 |3 Volltext | |
| 856 | 1 | |l CBO01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1511895 |3 Volltext | |
| 936 | |a BATCHLOAD | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL4625092 | ||
| 938 | |a EBSCOhost |b EBSC |n 1511895 | ||
| 938 | |a YBP Library Services |b YANK |n 13115636 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn957126295 |
|---|---|
| _version_ | 1813903729278058496 |
| adam_text | |
| any_adam_object | |
| author | Atta-ur-Rahman |
| author_facet | Atta-ur-Rahman |
| author_role | |
| author_sort | Atta-ur-Rahman |
| author_variant | a u au |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC523 |
| callnumber-raw | RC523 .F76 2016 |
| callnumber-search | RC523 .F76 2016 |
| callnumber-sort | RC 3523 F76 42016 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | PREFACE ; List of Contributors ; Should Physicians Screen for Dementia in the Primary Care Setting? ; INTRODUCTION; SECTION 1: SHOULD WE SCREEN FOR DEMENTIA?; Considerations in Screening for a Disease; Does Dementia Pass Muster as a Disease Worthy of Screening? ; CRITERION 1: How Prevalent and Costly is Alzheimer's disease?; CRITERION 2: Are Early Stages of Dementia not Obvious?; CRITERION 3: Are Screening Tools Cheap and Effective?; CRITERION 4: Does the Potential Harm from a False Positive or False Negative Test Outweigh the Positive Benefit from Screening? Criterion 5: Does Earlier Diagnosis of Dementia or Cognitive Impairment Make a Difference?Potential Non-Disease Indirect Benefits of Screening for Dementia; Potential Benefit of Early Detection #1: Alerting Physician to Potential Medication Compliance Problems; Potential Benefit of Early Detection #2: Alerting Physicians to the Risk of Post-Operative Delirium; Potential Benefit of Early Detection #3: Additional Time for Family Planning; Potential Benefit of Early Detection #4: Assessing Patient's Competence at Work and Managing Finances. Potential Benefit of Early Detection #5: Identifying Unsafe Drivers Before it is too latePotential Benefit #6-Identification of Potentially Reversible Dementias-and Reversing Them; Potential Benefit #7: Identification of Patients for Research Program Participation; Potential Benefit #8: Establishment of a Cognitive Baseline; The Key Question: Can Earlier Intervention in Dementia Make a Difference?; SECTION 2: BEDSIDE TESTS FOR DEMENTIA SCREENING ; The Mini-Mental State [44]; Montreal Cognitive Assement (MoCA) [47]; The Clock Draw Test; The Mini-Cog [58]. Buschke's Memory Impairment Screen [61]Semantic and Lexical Fluency Tasks as Screening Tools; The Hopkins Verbal Learning Test (HVLT) [71]; The Q & E (Quick and Easy); CONCLUSION; NOTES; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Endothelial Dysfunction and Chronic Low-Grade Inflammation as Potential Therapeutic Targets in Dementia Disorders ; INTRODUCTION; Endothelial Dysfunction and Chronic Low-Grade Inflammation as a Possible Link between Cardiometabolic Disorders and Dementia; Endothelial Dysfunction and Dementia. Treatment Options Targeting Endothelial Dysfunction and Chronic Low-Grade Inflammation in Dementia DisordersEndothelin Receptor Antagonists; Anti-Inflammatory Drugs; Nonsteroidal Anti-Inflammatory Drugs ; Cytokine Suppressive Anti-Inflammatory Drugs; CONCLUSION; ACKNOWLEDGEMENTS; CONFLICT OF INTEREST; REFERENCES; Recent Clinical Developments in Alzheimer's Disease ; INTRODUCTION; Therapeutic Strategies and Clinical Trials; Cholinergic Hypothesis; Amyloid Cascade Hypothesis; Inflammation in AD ; Metal Dyshomeostasis in AD; Future Development: Challenges and Recent Advances. |
| ctrlnum | (OCoLC)957126295 |
| dewey-full | 616.8/31 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.8/31 |
| dewey-search | 616.8/31 |
| dewey-sort | 3616.8 231 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05420cam a2200613 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn957126295</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20240705115654.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |n|---|||||</controlfield><controlfield tag="008">160820s2016 xx o 000 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">EBLCP</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">EBLCP</subfield><subfield code="d">YDX</subfield><subfield code="d">EBLCP</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCF</subfield><subfield code="d">N$T</subfield><subfield code="d">AGLDB</subfield><subfield code="d">D6H</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">VTS</subfield><subfield code="d">STF</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">UKSSU</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">956747086</subfield><subfield code="a">959534990</subfield><subfield code="a">959649506</subfield><subfield code="a">1010973709</subfield><subfield code="a">1087408883</subfield><subfield code="a">1162192367</subfield><subfield code="a">1264948669</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781681082318</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1681082314</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)957126295</subfield><subfield code="z">(OCoLC)956747086</subfield><subfield code="z">(OCoLC)959534990</subfield><subfield code="z">(OCoLC)959649506</subfield><subfield code="z">(OCoLC)1010973709</subfield><subfield code="z">(OCoLC)1087408883</subfield><subfield code="z">(OCoLC)1162192367</subfield><subfield code="z">(OCoLC)1264948669</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC523</subfield><subfield code="b">.F76 2016</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">HEA</subfield><subfield code="x">039000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">014000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">022000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">112000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">045000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.8/31</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Atta-ur-Rahman.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Sharjah :</subfield><subfield code="b">Bentham Science Publishers,</subfield><subfield code="c">2016.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (328 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">PREFACE ; List of Contributors ; Should Physicians Screen for Dementia in the Primary Care Setting? ; INTRODUCTION; SECTION 1: SHOULD WE SCREEN FOR DEMENTIA?; Considerations in Screening for a Disease; Does Dementia Pass Muster as a Disease Worthy of Screening? ; CRITERION 1: How Prevalent and Costly is Alzheimer's disease?; CRITERION 2: Are Early Stages of Dementia not Obvious?; CRITERION 3: Are Screening Tools Cheap and Effective?; CRITERION 4: Does the Potential Harm from a False Positive or False Negative Test Outweigh the Positive Benefit from Screening?</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Criterion 5: Does Earlier Diagnosis of Dementia or Cognitive Impairment Make a Difference?Potential Non-Disease Indirect Benefits of Screening for Dementia; Potential Benefit of Early Detection #1: Alerting Physician to Potential Medication Compliance Problems; Potential Benefit of Early Detection #2: Alerting Physicians to the Risk of Post-Operative Delirium; Potential Benefit of Early Detection #3: Additional Time for Family Planning; Potential Benefit of Early Detection #4: Assessing Patient's Competence at Work and Managing Finances.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Potential Benefit of Early Detection #5: Identifying Unsafe Drivers Before it is too latePotential Benefit #6-Identification of Potentially Reversible Dementias-and Reversing Them; Potential Benefit #7: Identification of Patients for Research Program Participation; Potential Benefit #8: Establishment of a Cognitive Baseline; The Key Question: Can Earlier Intervention in Dementia Make a Difference?; SECTION 2: BEDSIDE TESTS FOR DEMENTIA SCREENING ; The Mini-Mental State [44]; Montreal Cognitive Assement (MoCA) [47]; The Clock Draw Test; The Mini-Cog [58].</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Buschke's Memory Impairment Screen [61]Semantic and Lexical Fluency Tasks as Screening Tools; The Hopkins Verbal Learning Test (HVLT) [71]; The Q & E (Quick and Easy); CONCLUSION; NOTES; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Endothelial Dysfunction and Chronic Low-Grade Inflammation as Potential Therapeutic Targets in Dementia Disorders ; INTRODUCTION; Endothelial Dysfunction and Chronic Low-Grade Inflammation as a Possible Link between Cardiometabolic Disorders and Dementia; Endothelial Dysfunction and Dementia.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Treatment Options Targeting Endothelial Dysfunction and Chronic Low-Grade Inflammation in Dementia DisordersEndothelin Receptor Antagonists; Anti-Inflammatory Drugs; Nonsteroidal Anti-Inflammatory Drugs ; Cytokine Suppressive Anti-Inflammatory Drugs; CONCLUSION; ACKNOWLEDGEMENTS; CONFLICT OF INTEREST; REFERENCES; Recent Clinical Developments in Alzheimer's Disease ; INTRODUCTION; Therapeutic Strategies and Clinical Trials; Cholinergic Hypothesis; Amyloid Cascade Hypothesis; Inflammation in AD ; Metal Dyshomeostasis in AD; Future Development: Challenges and Recent Advances.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Alzheimer's disease.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85004080</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Alzheimer Disease</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D000544</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Maladie d'Alzheimer.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS</subfield><subfield code="x">Diseases</subfield><subfield code="x">General.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Clinical Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Diseases.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Evidence-Based Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Internal Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Alzheimer's disease</subfield><subfield code="2">fast</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5 (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PD39vvcqTypVW8gKYWfbBGd</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Atta-ur-Rahman.</subfield><subfield code="t">Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5.</subfield><subfield code="d">Sharjah : Bentham Science Publishers, ©2016</subfield><subfield code="z">9781681082325</subfield></datafield><datafield tag="856" ind1="1" ind2=" "><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1511895</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="1" ind2=" "><subfield code="l">CBO01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1511895</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="936" ind1=" " ind2=" "><subfield code="a">BATCHLOAD</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL4625092</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">1511895</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">13115636</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-ocn957126295 |
| illustrated | Not Illustrated |
| indexdate | 2024-10-25T16:23:18Z |
| institution | BVB |
| isbn | 9781681082318 1681082314 |
| language | English |
| oclc_num | 957126295 |
| open_access_boolean | |
| owner | MAIN |
| owner_facet | MAIN |
| physical | 1 online resource (328 pages) |
| psigel | ZDB-4-EBA |
| publishDate | 2016 |
| publishDateSearch | 2016 |
| publishDateSort | 2016 |
| publisher | Bentham Science Publishers, |
| record_format | marc |
| spelling | Atta-ur-Rahman. Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5. Sharjah : Bentham Science Publishers, 2016. 1 online resource (328 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Print version record. PREFACE ; List of Contributors ; Should Physicians Screen for Dementia in the Primary Care Setting? ; INTRODUCTION; SECTION 1: SHOULD WE SCREEN FOR DEMENTIA?; Considerations in Screening for a Disease; Does Dementia Pass Muster as a Disease Worthy of Screening? ; CRITERION 1: How Prevalent and Costly is Alzheimer's disease?; CRITERION 2: Are Early Stages of Dementia not Obvious?; CRITERION 3: Are Screening Tools Cheap and Effective?; CRITERION 4: Does the Potential Harm from a False Positive or False Negative Test Outweigh the Positive Benefit from Screening? Criterion 5: Does Earlier Diagnosis of Dementia or Cognitive Impairment Make a Difference?Potential Non-Disease Indirect Benefits of Screening for Dementia; Potential Benefit of Early Detection #1: Alerting Physician to Potential Medication Compliance Problems; Potential Benefit of Early Detection #2: Alerting Physicians to the Risk of Post-Operative Delirium; Potential Benefit of Early Detection #3: Additional Time for Family Planning; Potential Benefit of Early Detection #4: Assessing Patient's Competence at Work and Managing Finances. Potential Benefit of Early Detection #5: Identifying Unsafe Drivers Before it is too latePotential Benefit #6-Identification of Potentially Reversible Dementias-and Reversing Them; Potential Benefit #7: Identification of Patients for Research Program Participation; Potential Benefit #8: Establishment of a Cognitive Baseline; The Key Question: Can Earlier Intervention in Dementia Make a Difference?; SECTION 2: BEDSIDE TESTS FOR DEMENTIA SCREENING ; The Mini-Mental State [44]; Montreal Cognitive Assement (MoCA) [47]; The Clock Draw Test; The Mini-Cog [58]. Buschke's Memory Impairment Screen [61]Semantic and Lexical Fluency Tasks as Screening Tools; The Hopkins Verbal Learning Test (HVLT) [71]; The Q & E (Quick and Easy); CONCLUSION; NOTES; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Endothelial Dysfunction and Chronic Low-Grade Inflammation as Potential Therapeutic Targets in Dementia Disorders ; INTRODUCTION; Endothelial Dysfunction and Chronic Low-Grade Inflammation as a Possible Link between Cardiometabolic Disorders and Dementia; Endothelial Dysfunction and Dementia. Treatment Options Targeting Endothelial Dysfunction and Chronic Low-Grade Inflammation in Dementia DisordersEndothelin Receptor Antagonists; Anti-Inflammatory Drugs; Nonsteroidal Anti-Inflammatory Drugs ; Cytokine Suppressive Anti-Inflammatory Drugs; CONCLUSION; ACKNOWLEDGEMENTS; CONFLICT OF INTEREST; REFERENCES; Recent Clinical Developments in Alzheimer's Disease ; INTRODUCTION; Therapeutic Strategies and Clinical Trials; Cholinergic Hypothesis; Amyloid Cascade Hypothesis; Inflammation in AD ; Metal Dyshomeostasis in AD; Future Development: Challenges and Recent Advances. Alzheimer's disease. http://id.loc.gov/authorities/subjects/sh85004080 Alzheimer Disease https://id.nlm.nih.gov/mesh/D000544 Maladie d'Alzheimer. HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Alzheimer's disease fast has work: Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5 (Text) https://id.oclc.org/worldcat/entity/E39PD39vvcqTypVW8gKYWfbBGd https://id.oclc.org/worldcat/ontology/hasWork Print version: Atta-ur-Rahman. Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5. Sharjah : Bentham Science Publishers, ©2016 9781681082325 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1511895 Volltext CBO01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1511895 Volltext |
| spellingShingle | Atta-ur-Rahman Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5. PREFACE ; List of Contributors ; Should Physicians Screen for Dementia in the Primary Care Setting? ; INTRODUCTION; SECTION 1: SHOULD WE SCREEN FOR DEMENTIA?; Considerations in Screening for a Disease; Does Dementia Pass Muster as a Disease Worthy of Screening? ; CRITERION 1: How Prevalent and Costly is Alzheimer's disease?; CRITERION 2: Are Early Stages of Dementia not Obvious?; CRITERION 3: Are Screening Tools Cheap and Effective?; CRITERION 4: Does the Potential Harm from a False Positive or False Negative Test Outweigh the Positive Benefit from Screening? Criterion 5: Does Earlier Diagnosis of Dementia or Cognitive Impairment Make a Difference?Potential Non-Disease Indirect Benefits of Screening for Dementia; Potential Benefit of Early Detection #1: Alerting Physician to Potential Medication Compliance Problems; Potential Benefit of Early Detection #2: Alerting Physicians to the Risk of Post-Operative Delirium; Potential Benefit of Early Detection #3: Additional Time for Family Planning; Potential Benefit of Early Detection #4: Assessing Patient's Competence at Work and Managing Finances. Potential Benefit of Early Detection #5: Identifying Unsafe Drivers Before it is too latePotential Benefit #6-Identification of Potentially Reversible Dementias-and Reversing Them; Potential Benefit #7: Identification of Patients for Research Program Participation; Potential Benefit #8: Establishment of a Cognitive Baseline; The Key Question: Can Earlier Intervention in Dementia Make a Difference?; SECTION 2: BEDSIDE TESTS FOR DEMENTIA SCREENING ; The Mini-Mental State [44]; Montreal Cognitive Assement (MoCA) [47]; The Clock Draw Test; The Mini-Cog [58]. Buschke's Memory Impairment Screen [61]Semantic and Lexical Fluency Tasks as Screening Tools; The Hopkins Verbal Learning Test (HVLT) [71]; The Q & E (Quick and Easy); CONCLUSION; NOTES; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Endothelial Dysfunction and Chronic Low-Grade Inflammation as Potential Therapeutic Targets in Dementia Disorders ; INTRODUCTION; Endothelial Dysfunction and Chronic Low-Grade Inflammation as a Possible Link between Cardiometabolic Disorders and Dementia; Endothelial Dysfunction and Dementia. Treatment Options Targeting Endothelial Dysfunction and Chronic Low-Grade Inflammation in Dementia DisordersEndothelin Receptor Antagonists; Anti-Inflammatory Drugs; Nonsteroidal Anti-Inflammatory Drugs ; Cytokine Suppressive Anti-Inflammatory Drugs; CONCLUSION; ACKNOWLEDGEMENTS; CONFLICT OF INTEREST; REFERENCES; Recent Clinical Developments in Alzheimer's Disease ; INTRODUCTION; Therapeutic Strategies and Clinical Trials; Cholinergic Hypothesis; Amyloid Cascade Hypothesis; Inflammation in AD ; Metal Dyshomeostasis in AD; Future Development: Challenges and Recent Advances. Alzheimer's disease. http://id.loc.gov/authorities/subjects/sh85004080 Alzheimer Disease https://id.nlm.nih.gov/mesh/D000544 Maladie d'Alzheimer. HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Alzheimer's disease fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85004080 https://id.nlm.nih.gov/mesh/D000544 |
| title | Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5. |
| title_auth | Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5. |
| title_exact_search | Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5. |
| title_full | Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5. |
| title_fullStr | Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5. |
| title_full_unstemmed | Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5. |
| title_short | Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5. |
| title_sort | frontiers in clinical drug research alzheimer disorders volume 5 |
| topic | Alzheimer's disease. http://id.loc.gov/authorities/subjects/sh85004080 Alzheimer Disease https://id.nlm.nih.gov/mesh/D000544 Maladie d'Alzheimer. HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Alzheimer's disease fast |
| topic_facet | Alzheimer's disease. Alzheimer Disease Maladie d'Alzheimer. HEALTH & FITNESS Diseases General. MEDICAL Clinical Medicine. MEDICAL Diseases. MEDICAL Evidence-Based Medicine. MEDICAL Internal Medicine. Alzheimer's disease |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1511895 |
| work_keys_str_mv | AT attaurrahman frontiersinclinicaldrugresearchalzheimerdisordersvolume5 |